BioMab Partners with Vinmec to Accelerate Innovative Cancer Cell Therapies
Hanoi, Monday, 1 June 2026.
Announced today, June 1, 2026, BioMab and Vinmec’s partnership leverages technology to expand a 10-milliliter blood sample into one billion cancer-fighting cells, accelerating next-generation global oncology treatments.
Forging Global Alliances in Precision Oncology
On June 1, 2026, precision medicine developer BioMab, Inc. announced a strategic clinical collaboration with the Vinmec Healthcare System in Vietnam [1]. The partnership is designed to advance clinical testing and organoid studies utilizing BioMab’s proprietary Natural Killer (NK) Cell Expansion Kit, commercially designated as DSNK [1]. This cross-border alliance underscores a growing trend in the biotechnology sector, where companies leverage international clinical networks to accelerate the development pipelines of advanced oncology treatments [GPT].
The Mechanics and Economics of DSNK Technology
At the core of this partnership is BioMab’s DSNK technology, a chemically defined culture medium kit engineered to optimize the proliferation of cancer-fighting immune cells [1]. The system is capable of taking a 10-milliliter sample of peripheral blood and expanding it into more than one billion NK cells [1]. This exponential growth represents an approximate 3,000-fold expansion, yielding an average concentration of 100.000 million expanded cells per milliliter of the original blood drawn [1].
Strategic Implications and Future Outlook
Moving forward, the joint initiative plans to propel the clinical development of NK cell-based therapies while exploring translational applications through the use of organoid models [1]. These advanced, three-dimensional tissue cultures will allow researchers to simulate human organ responses in vitro, thereby facilitating the rapid development of next-generation immunotherapies tailored for cancer and other complex diseases [1].